As the Smirk Turns, FDA’s Opioid Plan, And A Gene Editing IPO

Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $149 per year, you reward quality independent biotech reporting, and encourage more.

You may also like

The Coronavirus Tsunami, Lyell’s $492M Megaround & Some Deals You Missed
Covid-19: Collective Problem-Solving Time
Covid-19 Spreads in Seattle, Gilead’s $4.9B Cancer Bet, & Thermo Grabs Qiagen
Gilead, Moderna Rise to the Occasion, Esperion Goes Back-to-Back, & Sangamo’s Big Neurology Deal